Some drugs, targeting pathways that influence TAMs recruitment and polarization—such as VEGF, TLR, HDAC, and CSF—have already been applied in clinical research for bladder cancer, while many others remain in the preclinical phase. Here, HDAC9 is linked to urinary bladder carcinoma.